Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix Using VeriStrat to Evaluate Kadmon's Tyrosine Kinase Inhibitor

NEW YORK (GenomeWeb News) – Biodesix today announced it is collaborating with biopharma Kadmon to evaluate the use of Biodesix's test for a non-small cell lung cancer study for Kadmon's reversible tyrosine kinase inhibitor.

The Phase 3 study is designed to compare Kadmon's TKI called KD019 with erlotinib in patients with stage IIIB/IV NSCLC who have progressed after first- or second-line chemotherapy. KD019 targets EGFR, HER2, VEGFR2 and 3, and SRC, and Biodesix's VeriStrat test will be used on serum samples from the study. The test will be evaluated for its effectiveness in identifying patients with better or worse outcomes following treatment with KD019, Biodesix said.

Terms of the deal were not disclosed.

Partnering with biopharmas has been a strategy of Biodesix to increase adoption of its VeriStrat, a laboratory developed test launched in 2009, and a company official said in January that it was progressing on those efforts.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.